Trump Administration Announces Medicare Drug Price Cuts via Biden-Era Law

The announcement concludes the second round of price negotiations mandated by the Inflation Reduction Act. This list includes high-profile medications such as Ozempic, Ibrance, and Xtandi. According to the Centers for Medicare & Medicaid Services, if these negotiated prices had been active last year, the program would have realized $12 billion in savings. The new rates are scheduled to take effect in 2027.

Despite the administration’s public embrace of these results, the political landscape remains fractious. President Donald Trump has previously moved to weaken the legislation, including signing measures that exempt certain high-cost drugs from future negotiations. Robert F. Kennedy Jr., secretary of the Health and Human Services Department, framed the latest outcome as a direct result of a presidential directive to reduce healthcare costs. However, Democratic lawmakers, including Sen. Ron Wyden, argue that Republican opposition to the original law undermines long-term progress for seniors. Advocacy groups like Public Citizen warn that the industry continues to lobby for further exemptions, threatening the viability of future price-setting efforts.